2016 - 2020
- TLC is listed on the Nasdaq Global Market (ticker: TLC)
- TLC initiates EXCELLENCE Phase III trial of TLC599 in knee osteoarthritis pain
- Phase II trial of TLC590 in bunionectomy successfully completed
- TLC ranks Top 5%in Corporate Governance Evaluations six years running
- TLC178 is designated by the US FDA as an orphan drug for the treatment of soft tissue sarcoma and a rare pediatric disease in the treatment of rhabdomyosarcoma.